甲磺酸阿帕替尼治疗晚期软组织肉瘤的临床观察  

Clinical observation of apatinib in the treatment of advanced soft tissue sarcoma

作　　者：贾昱娴[1] 陈千英 谭爱花[1] 刘燕[1] 覃芳卉[1] 农丽[1] JIA Yuxian;CHEN Qianying;TAN Aihua;LIU yan;QIN Fanghui;NONG Li(Department of Breast and Bone & Soft Tissue Oncology,the Affiliated Cancer Hospital of Guangxi Medical University,Nanning,Guangxi 530021,China)

机构地区：[1]广西医科大学附属肿瘤医院乳腺及骨软组织肿瘤内科,南宁530021

出　　处：《重庆医学》2022年第8期1344-1349,1357,共7页Chongqing medicine

基　　金：广西壮族自治区卫生和计划生育委员会自筹经费课题(Z20170426、Z20170447)。

摘　　要：目的探讨甲磺酸阿帕替尼在晚期软组织肉瘤(STS)中的疗效及安全性,并分析可能影响无疾病进展生存期(PFS)的因素。方法收集2015年5月至2019年12月就诊于该院的33例经甲磺酸阿帕替尼治疗的复发转移或局部晚期STS患者的临床资料,对甲磺酸阿帕替尼的疗效、PFS影响因素及不良反应进行回顾性分析。结果本组患者中位PFS(mPFS)为5.5个月(95%CI:3.8~8.2),中位总生存时间(mOS)为8.6个月(95%CI:6.7~11.3)。总缓解率(ORR)为12.12%,疾病控制率(DCR)为78.79%。单因素分析显示,患者的PFS与既往手术史[HR=0.32(0.13~0.83),P=0.019]及肿瘤转移[HR=0.29(0.09~0.97),P=0.045]有关。药物总体耐受性良好,3级以上不良反应包括:中性粒细胞减少(15.2%)、高血压(9.1%)、贫血(6.1%)。结论甲磺酸阿帕替尼对复发转移或局部晚期STS有一定疗效,安全性可控,值得临床进一步探索和推广。Objective To investigate the efficacy and safety of apatinib in the treatment of advanced soft tissue sarcoma(STS)in the real world,and to analyze the possible influencing factors of the progression free survival(PFS).Methods A total of 33 patients with advanced STS admitted to the Affiliated cancer hospital of Guangxi Medical University from May 2015 to July 2019 were selected and treated with apatinib.The clinical efficacy,influencing factors of PFS,and adverse reactions were retrospectively evaluated.Results The median progression free survival(mPFS)was 5.5 months(95%CI:3.8-8.2),the median overall survival(mOS)was 8.6 months(95%CI:6.7-11.3).The overall response rate(ORR)and the disease control rate(DCR)were 12.12%and 78.79%.Univariate analysis showed that PFS was correlated with whether surgery was taken[HR=0.32(0.13-0.83),P=0.019]and whether the tumor was metastatic[HR=0.29(0.09-0.97),P=0.045].Drug tolerance was generally good,the adverse reactions of gradeⅢand above were neutropenia(15.2%),hypertension(9.1%),anemia(6.1%).Conclusion Apatinib has certain efficacy in the treatment of advanced STS,and the safety is controllable,which is worthy of further clinical exploration and promotion.

关 键 词：甲磺酸阿帕替尼 软组织肉瘤 靶向治疗 有效性 安全性 

分 类 号：R739.9[医药卫生—肿瘤]